AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

AtaiBeckley Inc. (NASDAQ: ATAI) is set to launch a Phase 3 study for BPL-003, a treatment for treatment-resistant depression. Following a positive FDA meeting on March 3, the company is on track to start this pivotal program in Q2 2026.

This Phase 3 program includes two studies, ReConnection 1 and ReConnection 2, designed to evaluate dosing and long-term safety. With Breakthrough Therapy designation, ATAI aims to provide rapid, effective treatment options that could transform patient care.

Next up: The studies will assess the effectiveness of single and dual doses, potentially changing the landscape of depression treatment. ATAI believes BPL-003 could significantly reduce the number of treatments needed annually.